No headlines found.
No press releases found.
No news found.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Bio-Rad Laboratories Class B trades on the NYSE stock market under the symbol BIO.B.
As of July 6, 2026, BIO.B stock price was flat at $296.49 with 7 million shares trading.
BIO.B has a market cap of $8.00 billion. This is considered a Mid Cap stock.
In the last 3 years, BIO.B traded as high as $427.11 and as low as $222.64.
BIO.B has underperformed the market in the last year with a price return of +18.6% while the SPY ETF gained +22.0%. BIO.B has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +6.6% and -2.5%, respectively, while the SPY returned +14.6% and +0.4%, respectively.
BIO.B support price is $276.40 and resistance is $316.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIO.B shares will trade within this expected range on the day.
